Bioventix (LON:BVXP) Shares Cross Above 50 Day Moving Average - Time to Sell?

Key Points

• Bioventix shares crossed above their 50-day moving average
• The company has a market cap of £86.21 million and a PE of 11.74, showing strong profitability metrics (net margin 59.3% and ROE 65.8%), while analysts forecast roughly GBX 166.31 EPS for the current year.
• Insider buying was reported last quarter — insiders purchased 2,131 shares (notably Peter John Harrison bought 1,065 at GBX 1,849 and Ian James Nicholson 1,000 at GBX 1,848) and insiders now own 6.16% of the company.

Bioventix PLC (LON:BVXP - Get Free Report)'s share price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 1,604.23 and traded as high as GBX 1,750. Bioventix shares last traded at GBX 1,660, with a volume of 9,220 shares changing hands.

Bioventix Stock Performance

The company has a market cap of £86.21 million, a PE ratio of 11.74 and a beta of 0.48. The stock's 50 day moving average price is GBX 1,604.23 and its 200-day moving average price is GBX 1,803.34.

Bioventix (LON:BVXP - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share for the quarter. The business had revenue of GBX 615.88 billion during the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. On average, analysts anticipate that Bioventix PLC will post 166.3066955 EPS for the current year.

Insider Buying and Selling at Bioventix

In other news, insider Peter John Harrison purchased 1,065 shares of the company's stock in a transaction on Wednesday, April 8th. The stock was acquired at an average price of GBX 1,849 per share, with a total value of £19,691.85. Also, insider Ian James Nicholson purchased 1,000 shares of the company's stock in a transaction on Friday, April 10th. The shares were purchased at an average cost of GBX 1,848 per share, with a total value of £18,480. Insiders bought 2,131 shares of company stock valued at $3,927,999 in the last quarter. Company insiders own 6.16% of the company's stock.

Bioventix Company Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.